drugset / Trial / NCT02260024

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

NCT02260024

Phase 1 Completed 15 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of the study was to estimate the magnitude of the error in the prediction of in vivo bioavailability (AUC0-30,Cmax) by means of in vitro dissolution data applying the methods of IVIVC. The secondary objective of the study was to investigate whether the intake of food 30 minutes prior to drug administration affects the systemic exposure of pramipexole SR C2 or not

Timeline

Start
2005-10
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pramipexole Unknown 0.375 mg Oral

Indications

No indication recorded.